1. Home
  2. MMLP vs GANX Comparison

MMLP vs GANX Comparison

Compare MMLP & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Martin Midstream Partners L.P. Limited Partnership

MMLP

Martin Midstream Partners L.P. Limited Partnership

N/A

Current Price

$2.45

Market Cap

95.1M

Sector

Energy

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.75

Market Cap

78.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMLP
GANX
Founded
2002
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.1M
78.5M
IPO Year
2002
2021

Fundamental Metrics

Financial Performance
Metric
MMLP
GANX
Price
$2.45
$1.75
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$3.00
$7.50
AVG Volume (30 Days)
19.7K
792.5K
Earning Date
04-22-2026
05-13-2026
Dividend Yield
0.78%
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
$1,653,009,000.00
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.65
N/A
52 Week Low
$1.89
$1.41
52 Week High
$3.54
$4.34

Technical Indicators

Market Signals
Indicator
MMLP
GANX
Relative Strength Index (RSI) 53.23 48.92
Support Level $2.22 $1.66
Resistance Level $2.49 $2.09
Average True Range (ATR) 0.12 0.11
MACD 0.03 0.00
Stochastic Oscillator 82.05 60.00

Price Performance

Historical Comparison
MMLP
GANX

About MMLP Martin Midstream Partners L.P. Limited Partnership

Martin Midstream Partners LP has a diverse set of operations focused on the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products, including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing, and distribution; and natural gas liquids marketing, distribution and transportation services. The company operates in four segment Terminalling and storage, Transportation, Sulfur service, and Specialty products segment. The majority of the revenue is derived from the Specialty products segment.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: